News and Media – CrannMed

Resorbable vs Permanent Embolization

Resorbable vs Permanent embolic in MSK embolization – how does the embolic profile influence procedural approach?The permanence of the embolic affects endpoint selection, extent…

Pilot Research Presented at SIR 2025

Pilot Research investigating the feasibility of lumbar treatment using SakuraBead was presented at the prestigious SIR Conference in April 2025 by Asst Prof Jessie Stewart…

First patients treated in CrannMed FDA-approved Knee Osteoarthritis study

We are delighted to share that the first 4 patients have been enrolled and treated in our FDA approved IDE study. A huge thank…

Pilot Trial of SakuraBead Successful for Chronic Knee Pain

All of us at CrannMed were extremely proud to treat our first patients. We treated patients suffering from long-term chronic knee pain. All reported a…

CrannMed announced as recipient of Government funding under the Disruptive Technology and Innovation Fund (DTIF)

We are delighted to have been confirmed as one of the companies approved for DTIF grant funding this year. This is awarded to projects…

CrannMed obtains second “Breakthrough Device Designation” from the FDA for Adhesive Capsulitis

We are thrilled to announce that the FDA has granted us our second Breakthrough Device Designation. This designation is specifically for the application of our…

SakuraBead pre-clinical data presented at GEST MSK 2023

We were delighted to have our pre-clinical data on SakuraBead, our resorbable embolization microspheres, presented for the first time at the inaugural GEST MSK 2023…

New Cleanroom Installation

Last month, we finished the installation and validation of our new, class 8 cleanroom. This was the final step in allowing us to build finished,…

CrannMed moves into new offices – expanding footprint and positioning for growth

CrannMed has expanded into new premises. The company, which formed in 2018, is moving to 6,000 sq ft premises in the Galway Technology Park, Parkmore,…

CrannMed receives €3.5M from Horizon EIC Accelerator

CrannMed has been awarded €3.5m via the highly competitive EU funded Horizon EIC Accelerator project instrument. This 2-year project will fund a pivotal clinical trial,…